71Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Greece
Neuroscience Intelligence
Greece neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #28 of 50 · Data maturity A · Research score 34.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
31Recruiting trials
61Publications
52Institutions
Executive interpretation
Greece ranks #28 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC109 recruiting
Aristotle University Of Thessaloniki52 recruiting
Boehringer Ingelheim40 recruiting
Hoffmann-La Roche32 recruiting
Attikon Hospital21 recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany22 recruiting
GlaxoSmithKline20 recruiting
Bristol-Myers Squibb22 recruiting
Eli Lilly and Company20 recruiting
National and Kapodistrian University of Athens21 recruiting
Disease activity
Parkinsons12trials
Alzheimers11trials
Epilepsy9trials
Multiple Sclerosis7trials
Schizophrenia6trials
Stroke5trials
Depression3trials
Adhd2trials
Neuro Oncology2trials
Neuromuscular2trials
Research institutions
Technical University of CreteOpenAlexlinked institution
National Technical University of AthensOpenAlexlinked institution
Athens EuroclinicOpenAlexlinked institution
Papageorgiou General HospitalOpenAlexlinked institution
Hellenic Cardiological SocietyOpenAlexlinked institution
Academy of AthensOpenAlexlinked institution
General-Maternity District Hospital Helena VenizelouOpenAlexlinked institution
Laiko General Hospital of AthensOpenAlexlinked institution
University Hospital of LarissaOpenAlexlinked institution
University of PatrasOpenAlexlinked institution
Clinical evidence trail
NCT07672938Effects of Hydroxytyrosol-Rich Olive Polyphenol Dietary Supplement Combined With Mediterranean Diet Adherence on the Cognitive Health of Patients With Mild Cognitive ImpairmentRECRUITING
NCT07289061Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain FunctionRECRUITING
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07113119Effects of a Long-term Exercise Training Program on the Functional Capacity and Health-related Quality of Life in Inpatients With Psychotic DisordersRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT07001449Effectiveness of Communication-Focused Pain Neuroscience Education in Chronic Musculoskeletal PainRECRUITING
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
Research evidence trail
PUBMEDRituximab treatment in AChR-positive generalized myasthenia gravis within two years of diagnosis.2026-12-01
PUBMEDSaccadic eye movements based classification of patients with obsessive-compulsive disorder, patients with schizophrenia and healthy controls using artificial neural networks.2026-12-01
PUBMEDClinical parameters affecting the course of amyotrophic lateral sclerosis: a longitudinal analysis of the Greek registry for amyotrophic lateral sclerosis (ALS-GR).2026-11-01
PUBMEDVitamin D receptor gene variants and their association with clinical phenotypes of multiple sclerosis.2026-11-01
PUBMEDDentate gyrus immaturity and region-specific synaptic and autophagy alterations across hippocampal subfields in schizophrenia.2026-11-01
PUBMEDAlexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy.2026-11-01
PUBMEDFood insecurity and pain burden in patients with multiple sclerosis and rheumatoid arthritis: A comparative case-control study.2026-10-23
PUBMEDGlial-specific polygenic risk and mediterranean diet impact cognitive performance and dementia-related outcomes in the elderly.2026-10-22
PUBMEDPsychological Functioning and Parent-Child Mental Health Interrelations in Pediatric Gastrointestinal Autoimmune Disorders.2026-10-07
PUBMEDWhat shapes health-related quality of life in drug-resistant epilepsy? Clinical, emotional, and cognitive predictors.2026-10-05
PUBMEDEffectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.2026-10-01
PUBMEDA Schizophrenia-Spectrum Presentation with Panda Sign: Huntington's Disease Confirmed, Wilson Disease Excluded.2026-10-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.